{"filing":{"accession_number":"0001104659-26-075730","cik":"0001446847","ticker":"IRWD","company_name":"IRONWOOD PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"tm2618313d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465926075730/tm2618313d1_8k.htm"},"events":[{"id":11844,"run_id":10420,"accession_number":"0001104659-26-075730","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Ironwood Pharmaceuticals held its Annual Meeting of Stockholders and disclosed voting results on multiple matters, including election of eight directors, advisory approval of named executive officer compensation, approval of a Plan Amendment increasing equity incentive plan shares by 10 million, and ratification of KPMG LLP as independent auditor.","company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8536,"accession_number":"0001104659-26-075730","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2019 Equity Incentive Plan that increases available shares by 10,000,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves a material modification to the equity compensation plan that affects the pool of shares available for future grants to directors and officers. The magnitude of the increase (10 million shares) and the stockholder vote requirement make this material to investors assessing dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:10.282510+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8537,"accession_number":"0001104659-26-075730","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Ironwood Pharmaceuticals' Annual Meeting of Stockholders, including election of eight directors, advisory approval of named executive officer compensation, approval of a Plan Amendment, and ratification of KPMG LLP as independent auditor. The comprehensive tabulation of votes cast (For, Against, Abstain, and Broker Non-Votes) for each matter is the hallmark of shareholder vote results disclosure required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:10.282510+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8536,"accession_number":"0001104659-26-075730","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2019 Equity Incentive Plan that increases available shares by 10,000,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves a material modification to the equity compensation plan that affects the pool of shares available for future grants to directors and officers. The magnitude of the increase (10 million shares) and the stockholder vote requirement make this material to investors assessing dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:10.282510+00:00","company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","filing_date":"2026-06-18"},{"id":8537,"accession_number":"0001104659-26-075730","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Ironwood Pharmaceuticals' Annual Meeting of Stockholders, including election of eight directors, advisory approval of named executive officer compensation, approval of a Plan Amendment, and ratification of KPMG LLP as independent auditor. The comprehensive tabulation of votes cast (For, Against, Abstain, and Broker Non-Votes) for each matter is the hallmark of shareholder vote results disclosure required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:16:10.282510+00:00","company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","filing_date":"2026-06-18"}]}